Clinical OMICS

JAN-FEB 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 19 of 51 18 Clinical OMICs January/February 20 have a combination of the genomic data with the trial data that you were gathering, you would ure out where is my drug working and why—and where is it not working and why. This is incredibly important for the economics of clinical trials, and also for patients. Second, it is clear that many diseases—and cancer is a critical one, but not the only one—are a spectrum of disease, and if you can identify genetically what is driv- ing it, what is the underlying genetic causative agent, [you can] stratify the patients and provide treatments in a much more effective What challenges do you think translational informatics will face in the future? Daly: The biggest challenge will be sourcing the data. Patients have a lot of say now about what happens with their data, so it's about obtaining the appropri- ate patient consent. The strategic high ground in this flow is the patient and getting the pat understand exactly what you are going to do [with their data]. This is important because everything that is done downstream from the patients needs back to the patient. You need to show the patient why what you are doing is good and why they should be participating. That's a challenge. This explains why the U.K. was so successful in building their cohort, becasue essentially there is a very large group of citizens in the U.K. who trust the government and the health system, and are willing to make their data available. That is not true everywhere in the world. The second problem is that most of the data is in dif- ferent formats, so figuring out how to h data is a critical element. What problems does having data and tools available in the cloud solve for researchers? Daly: The emerging challenges are how do you build and manage a community of researchers in a way that allows you to control the data? One of the things that having a platform like this allows you to do is un-silo data and promote data sharing. The catch is you need to do it in a highly secure and compliant way. The com- pliance element has increased dramatically in the last 24 months. Everyone knows about GDPR, but that is not the only set of requirements. Without a global network such as the one we have built, how would you have hundreds, or even thou- sands, of collaborators to be able to control access to the data, track what they do, and make sure you are com- pliant with all the different of regula ferent locales. That is a scale problem well beyond what any individual institution can do. What do you envision in the coming years? Daly: The velocity of this technology and the use case is extraordinarily high. But if the voyage ends at 100, we are at about 15 right now. It is still early for what is known about the genome and its impact on disease. It is going to be decades before we get over the 50% line, in my view. Photographer is my life / Moment / Getty Image

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2019